Integral Dental has announced the launch of its first product, OraclePI, which according to the company is the only early diagnostic test for peri-implantitis. The test delivers a disease diagnosis and personalized care plan recommendations based on patient-specific data.
Dental implants are an important option for patients with missing teeth. While implant success rates are high, the greatest risk of failure is an infection of the surrounding tissue, called peri-implantitis. OraclePI enables clinicians to gain insight into the bacteria present at the implant site, it diagnoses the state of the infection, and it makes recommendations on the most effective antibiotics and other treatments.
"This has the potential to improve patient outcomes and drive profitability for dental practices," Rachel Raymond, CEO of Integral Dental, said. "As the demand for implants grows, we're excited to offer an option for personalized management."
Diagnosing peri-implantitis is the beginning of Integral's technology platform, according to the company. Integral's vision extends beyond oral health to address systemic diseases triggered by oral pathogens, such as cardiovascular disease, preterm birth, rheumatoid arthritis, and colon cancer. Integral Dental continues to explore innovative applications for OraclePI, building bridges between oral health and broader medical care, it said.
OraclePI is available for purchase and is offered in 10 kit packs for a limited time. To learn more, visit IntegralDental.bio.
